Digest Network Come funziona
Network
/
Società
En
Non verificato

Enveda

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

14 comunicati stampa

Guarda tutti i comunicati
18/08/2026
Multimedialità
Industria
Salute
Fitness
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Enveda Reports Positive Phase 1 Results for ENV-308, the First Pill Designed From the Chemistry of Exercise
Fonte
Enveda
Emittente
Business Wire
1.00
0
23/07/2026
Multimedialità
Eventi
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Enveda’s Positive Phase 1B Results for ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, Were Presented at AAD Innovation Academy; Additional Details to Be Shared at EADV
Fonte
Enveda
Emittente
Business Wire
1.00
0
15/04/2026
Mercato del lavoro
Salute
Tecnica
Scienza
Farmaceutica
Biotecnologia
Enveda Appoints Christopher K. Porter, MBA, JD as Senior Vice President, Clinical Operations
Fonte
Enveda
Emittente
Business Wire
1.00
0
31/03/2026
Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial of Patients with Moderate-to-Severe Atopic Dermatitis
Fonte
Enveda
Emittente
Business Wire
1.00
0
23/12/2025
Scienza
Tecnica
Igiene alimentare
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Industria
Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease
Fonte
Enveda
Emittente
Business Wire
1.00
0
17/12/2025
Mercato del lavoro
Industria
Scienza
Tecnica
Igiene alimentare
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead Metabolic Disease Strategy
Fonte
Enveda
Emittente
Business Wire
1.00
0
09/12/2025
Industria
Igiene alimentare
Information Technology
Tecnica
Farmaceutica
Sanità
Biotecnologia
Medicina - Varie
Scienza
Software
Salute
Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma
Fonte
Enveda
Emittente
Business Wire
1.00
0
04/09/2025
Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors
Fonte
Enveda
Emittente
Business Wire
1.00
0
28/05/2025
Tecnica
Biotecnologia
Salute
Sanità
Farmaceutica
Scienza
Tecnologie Varie
Software
Medicina - Varie
Industria
Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis
Fonte
Enveda
Emittente
Business Wire
1.00
0
26/02/2025
Scienza
Tecnica
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
Fonte
Enveda
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0